PpSP32-like protein as a marker of human exposure to Phlebotomus argentipes in Leishmania donovani foci in Bangladesh

Sumova, Petra; Sanjoba, Chizu; Willen, Laura; Polanska, Nikola; Matsumoto, Yoshitsugu; Noiri, Eisei; Paul, Shyamal Kumar; Özbel, Yusuf; Volf, Petr

doi:10.1016/j.ijpara.2021.05.006

Cited by 4 publications

(4 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to India [32], the evaluation of the composite recombinant antigen (rPagSP02 + rPagSP06) using indirect ELISA proved to be as effective as SGH in detecting anti-salivary IgG antibodies in Sri Lanka, providing an alternative that is less labor intensive and more reproducible. Interestingly, the level of exposure and the percentage of individuals testing positive for vector exposure were comparable to, or even higher than, those reported in previous studies conducted in various endemic regions such as Bangladesh in August 2014 and India in November 2019 [30,32]. Of note, our study was conducted during a period when the sand y density was high.…”

Section: Discussionsupporting

confidence: 83%

“…A PpSP32-like (PagSP06) was considered as a biomarker of Ph. argentipes exposure in humans in Bangladesh [30]. A more recent study demonstrated that combining PagSP06 and PagSP02 improves performance of the biomarker, resulting in a noticeable decrease in cross-reactive antibodies [32].…”

Section: Discussionmentioning

confidence: 99%

“…Studies conducted in India, Nepal and Bangladesh demonstrated the use of anti-salivary antibodies to estimate human exposure to Ph. argentipes bites [28][29][30][31][32]. A combination of two recombinant Ph.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

rPagSP02+rPagSP06 recombinant salivary antigen is a reliable biomarker for evaluating exposure to Phlebotomus argentipes in Sri Lanka

Piyasiri,

Senanayake,

Samaranayake

et al. 2024

Preprint

View full text Add to dashboard Cite

Phlebotomus argentipes is the established vector of leishmaniasis in the Indian sub-continent. Antibodies to sand fly salivary antigens are biomarkers for vector-host exposure in leishmaniasis-endemic regions. Ph. argentipes transmits Leishmania donovani in Sri Lanka, primarily causing cutaneous leishmaniasis (CL). Our study compared the performance of salivary gland homogenate (SGH) from a lab-reared local strain of Ph. argentipes females to a composite recombinant salivary biomarker (rPagSP02 + rPagSP06) in a CL-endemic population. Sera from 546 healthy individuals, 30 CL patients, and 15 non-endemic individuals were collected. Western blot analysis of Ph. argentipes SGH identified immunogenic bands between 15 kDa and 67 kDa, with bands of predicted molecular weight ∼of 15 kDa (SP02) and ∼28–30 kDa (SP06) as the major antibody targets. Indirect ELISAs using SGH or rPagSP02 + rPagSP06 antigens showed high sensitivity (96.7%) and specificity (100%), detecting comparable seropositivity in endemic populations. rPagSP02 + rPagSP06 exhibited enhanced discriminatory ability, supported by a strong positive correlation (r = 0.869) with SGH. Our findings indicate that the composite rPagSP02 + rPagSP06 salivary biomarker effectively identifies Ph. argentipes exposure in individuals living in Sri Lanka, showing promising potential for use in surveillance. These findings should be further validated to confirm the epidemiological applications in leishmaniasis-endemic regions.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

rPagSP02+rPagSP06 recombinant salivary antigen is a reliable biomarker for evaluating exposure to Phlebotomus argentipes in Sri Lanka

Piyasiri,

Senanayake,

Samaranayake

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…A vaccine against CL caused by L. major may not necessarily have effectivity against the New World forms of diseases, including MCL and DCL [29]. Nonetheless, various vaccination strategies, such as recombinant antigens, DNA vaccines, salivary gland proteins, killed parasites, and live attenuated parasites exist to treat leishmaniasis [30][31][32][33][34].…”

Section: Vaccination Strategies In Leishmaniasismentioning

confidence: 99%

Leishmania Vaccines: the Current Situation with Its Promising Aspect for the Future

Dinc¹

2022

Korean J Parasitol

View full text Add to dashboard Cite

Leishmaniasis is a serious parasitic disease caused by Leishmania spp. transmitted through sandfly bites. This disease is a major public health concern worldwide. It can occur in 3 different clinical forms: cutaneous, mucocutaneous, and visceral Leishmaniasis (CL, MCL, and VL, respectively), caused by different Leishmania spp. Currently, licensed vaccines are unavailable for the treatment of human Leishmaniasis. The treatment and prevention of this disease rely mainly on chemotherapeutics, which are highly toxic and have an increasing resistance problem. The development of a safe, effective, and affordable vaccine for all forms of vector-borne disease is urgently needed to block transmission of the parasite between the host and vector. Immunological mechanisms in the pathogenesis of Leishmaniasis are complex. IL-12-driven Th1-type immune response plays a crucial role in host protection. The essential purpose of vaccination is to establish a protective immune response. To date, numerous vaccine studies have been conducted using live/attenuated/killed parasites, fractionated parasites, subunits, recombinant or DNA technology, delivery systems, and chimeric peptides. Most of these studies were limited to animals. In addition, standardization has not been achieved in these studies due to the differences in the virulence dynamics of the Leishmania spp. and the feasibility of the adjuvants. More studies are needed to develop a safe and effective vaccine, which is the most promising approach against Leishmania infection.

show abstract

A Composite Recombinant Salivary Proteins Biomarker for Phlebotomus argentipes Provides a Surveillance Tool Postelimination of Visceral Leishmaniasis in India

Iniguez

Saha

Petrellis

et al. 2022

The Journal of Infectious Diseases

View full text Add to dashboard Cite

Incidence of visceral leishmaniasis (VL) in the Indian subcontinent (ISC) has declined by more than 95% since initiation of the elimination program in 2005. As the ISC transitions to the post-elimination surveillance phase, an accurate measurement of human-vector contact is needed to assure long-term success. To develop this tool, we identified PagSP02 and PagSP06 from saliva of Phlebotomus argentipes, the vector of Leishmania donovani in the ISC, as immunodominant proteins in humans. We also established the absence of cross-reactivity with Ph. papatasi saliva, the only other human-biting sand fly in the ISC. Importantly, by combining recombinant rPagSP02 and rPagSP06 we achieved greater antibody recognition and specificity than single salivary proteins. The Receiver Operating Characteristics curve for rPagSP02 + rPagSP06 predicts exposure to Ph. argentipes bites with 90% specificity and 87% sensitivity compared to negative control sera (P >0.0001). Overall, rPagSP02 + rPagSP06 provides an effective surveillance tool for monitoring vector control efforts post-VL elimination.

show abstract

PpSP32-like protein as a marker of human exposure to Phlebotomus argentipes in Leishmania donovani foci in Bangladesh

Abstract: Graphical abstract

Cited by 4 publications

References 48 publications

rPagSP02+rPagSP06 recombinant salivary antigen is a reliable biomarker for evaluating exposure to Phlebotomus argentipes in Sri Lanka

rPagSP02+rPagSP06 recombinant salivary antigen is a reliable biomarker for evaluating exposure to Phlebotomus argentipes in Sri Lanka

Leishmania Vaccines: the Current Situation with Its Promising Aspect for the Future

A Composite Recombinant Salivary Proteins Biomarker for Phlebotomus argentipes Provides a Surveillance Tool Postelimination of Visceral Leishmaniasis in India

Contact Info

Product

Resources

About